Three ways 340B is failing vulnerable patients

The 340B Drug Pricing Program is 30 years old this year, but asThe New York Timesrecently spelled out, the program has become a profit engine for large health systems over the years instead of a program that helps vulnerable, low-income patients. Powerful hospitals have twisted the program to boost their bottom line.
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B Source Type: news